Guangzhou, China and Woodland Hills, USA: Angitia Biopharmaceuticals is delighted to announce the appointment of Mr. David A Piacquad as an Independent Board Director.

Guangzhou, Guangdong, China, and Woodland Hills, California, USA: Angitia Biopharmaceuticals (Angitia) today announced the successful conclusion and positive top-line results of a phase 1/2 study entitled ‘A randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of a single intervertebral administration of AGA111 in patients with degenerative disc disease undergoing interbody fusion’. The results from this trial demonstrated an excellent safety profile and preliminary efficacy in increasing fusion rate and improving clinical outcome.

Angitia Biopharmaceuticals Announces First Subject Dosed in Phase I Clinical Trial of AGA2118